Abstract 178P
Background
Liquid biopsy (LBx) based comprehensive genomic profiling (CGP) is increasingly used in clinical practice. The sensitivity of LBx is influenced by levels of circulating tumor DNA (ctDNA), but limited data is available correlating ctDNA levels with clinical parameters and their effect on detecting distinct genomic alterations in metastatic colorectal cancer (mCRC).
Methods
LBx using FoundationOne Liquid CDx was performed on plasma ctDNA at baseline in patients with RAS/BRAFV600E wild type (WT) mCRC enrolled in the CAPRI-2 GOIM trial.
Results
Among 205 patients with available baseline LBx, median ctDNA tumor fraction (TF) was 25% (range, 0.1-86%). ctDNA TF was higher among patients presenting with isolated liver involvement (n=68, ctDNA 34.5% [IQR 15.0-54.2]) or liver with other metastatic sites (n=90, ctDNA 30.0% [IQR 9.2-56.3]) as compared to those showing only lung (n=11, ctDNA 1.3% [IQR 1.0-2.3]; P<0.001) or lymph nodes involvement (n=13, ctDNA 1.7% [IQR 1.23-37.5]; P<0.001). ctDNA TF positively correlated with higher number of metastatic sites (≥3 anatomical sites: ctDNA 51% [IQR 17-66.5] vs. 1-2 sites: ctDNA 22% [IQR 2.3-49]; P<0.001), albeit only liver involvement (P<0.001) but not the number of anatomical sites (P=0.16) associated with higher ctDNA TF in the multivariable model. Samples showing copy number variants (CNV) showed higher ctDNA TF (LBx amplifications (n=64): ctDNA 45% [IQR 25-58.8] vs. 16% [IQR 1.7-48.5]; P<0.001; LBx deletions (n=12): ctDNA 56% [IQR 46.8-68.2] vs. 25% [IQR 3.3-51.0]; P<0.001), with no deletions and only 4 amplifications detected among samples showing a ctDNA TF below 10%. Patients showing a high Tumor mutational burden (TMB) (n=20) showed a numerical higher ctDNA TF (ctDNA 37.5% [IQR 16.5 vs. 56.4] vs. 28% [IQR 4.05-51.2]; P=0.08), with only one TMB-high case showing a ctDNA TF below 10%.
Conclusions
ctDNA levels depend on metastatic sites, with significantly lower levels in patients without liver involvement. Distinct alteration classes exhibit distinct analytical sensitivity, with CNV requiring higher ctDNA levels for detection.
Editorial acknowledgement
Clinical trial identification
EudraCT 2020-003008-15; NCT05312398.
Legal entity responsible for the study
The authors.
Funding
The CAPRI 2-GOIM clinical trial is partially supported by a research grant from Merck KGaA Italy.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Early cancer detection from liquid biopsy using cell-free RNA
Presenter: Joao Curado
Session: Cocktail & Poster Display session
Resources:
Abstract
49P - Numb serves as a prognostic biomarker and promotes lung adenocarcinoma brain metastasis
Presenter: Yanyan Zhao
Session: Cocktail & Poster Display session
Resources:
Abstract
50P - Integrin-fibronectin interplay is a pivotal biological and clinical determinant in papillary thyroid carcinoma
Presenter: Domenico Rocco
Session: Cocktail & Poster Display session
Resources:
Abstract
51P - Correlation of IL-6 and c-reactive protein levels with the stage, differentiation and types of colorectal cancer
Presenter: MOHAMED MAHBOOB ALI
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - RAS mutation status and mutation type as potential predictive biomarkers for thrombosis in metastatic colorectal cancer: A tertiary center 12-year cohort analysis
Presenter: José Leão Mendes
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Assessment of cancer testis antigen 45 for diagnostic and prognostic applications in ovarian cancer
Presenter: Harshita Dubey
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - Integrative omics workflow identifies credible druggable targets in high-grade serous cancer
Presenter: Taru Muranen
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - Impact of IHC/PCR discordance on immunotherapy (ICI) response in colorectal cancer (CRC) patients and prospects of liquid biopsy (LB) to replace conventional methods: Survival analysis of BLOOMSI trial
Presenter: Alexandra Lebedeva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Response of gastric adenocarcinoma to neoadjuvant chemotherapy with respect to the presence or absence of HER2 overexpression: A prospective observational study
Presenter: Pratap Deb
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - NSCLC genomic complexity: Insights from comprehensive molecular profiling in the era of precision medicine
Presenter: Preeti Paliwal
Session: Cocktail & Poster Display session
Resources:
Abstract